IL-33/ST2 involves the immunopathology of ocular toxoplasmosis in murine model

Parasitology Research

Volumn 114, Issue 5, 2015, Pages 1897-1905

  Tong, Xinxin ^a   Lu, Fangli ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

IL 33; KM mice; Ocular infection; ST2; Toxoplasma gondii

Indexed keywords

IL1RL1 PROTEIN, MOUSE; IL33 PROTEIN, MOUSE; INTERLEUKIN 33; INTERLEUKIN RECEPTOR;

ANIMAL; DISEASE MODEL; FEMALE; IMMUNOLOGY; MOUSE; TOXOPLASMA; TOXOPLASMOSIS;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; INTERLEUKIN-33; MICE; RECEPTORS, INTERLEUKIN; TOXOPLASMA; TOXOPLASMOSIS, OCULAR;

EID: 84939982681     PISSN: 09320113     EISSN: 14321955     Source Type: Journal    
DOI: 10.1007/s00436-015-4377-3     Document Type: Article

References (34)

1. Barbour M, Allan D, Xu H, Pei C, Chen M, Niedbala W, Fukada SY, Besnard AG, Alves-Filho JC, Tong X, Forrester JV, Liew FY, Jiang HR (2014) IL-33 attenuates the development of experimental autoimmune uveitis. IL-33 attenuates the development of experimental autoimmune uveitis. Eur J Immunol 44(11):3320–3329
2. Charles E, Callegan MC, Blader IJ (2007) The SAG1 Toxoplasma gondii surface protein is not required for acute ocular toxoplasmosis in mice. 75(4):2079–2083
3. da Luz FA, Oliveira AP, Borges D, Brígido PC, Silva MJ (2014) The physiopathological role of IL-33: new highlights in bone biology and a proposed role in periodontal disease. Mediators Inflamm 2014:342410
4. Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519–550
5. Garlanda C, Dinarello CA, Mantovani A (2013) The interleukin-1 family: back to the future. Immunity 39(6):1003–1018
6. Hayashi S, Chan CC, Gazzinelli RT, Pham NT, Cheung MK, Roberge FG (1996) Protective role of nitric oxide in ocular toxoplasmosis. Br J Ophthalmol 80(7):644–648
7. Hazlett LD, McClellan SA, Barrett RP, Huang X, Zhang Y, Wu M, van Rooijen N, Szliter E (2010) IL-33 shifts macrophage polarization, promoting resistance against Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 51(3):1524–1532
8. Holland GN (2003) Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. Am J Ophthalmol 136(6):973–988
9. Holland GN (2004) Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management. Am J Ophthalmol 137(1):1–17
10. Hunter CA, Chizzonite R, Remington JS (1995) IL-1 beta is required for IL-12 to induce production of IFN-gamma by NK cells. A role for IL-1 beta in the T cell-independent mechanism of resistance against intracellular pathogens. J Immunol 155(9):4347–4354
11. Jash A, Kwon HK, Sahoo A, Lee CG, So JS, Kim J, Oh YK, Kim YB, Im SH (2010) Topical application of porcine placenta extract inhibits the progression of experimental contact hypersensitivity. J Ethnopharmacol 133(2):654–662
12. Jones LA, Alexander J, Roberts CW (2006) Ocular toxoplasmosis: in the storm of the eye. Parasite Immunol 28(12):635–642
13. Jones LA, Roberts F, Nickdel MB, Brombacher F, McKenzie AN, Henriquez FL, Alexander J, Roberts CW (2010) IL-33 receptor (T1/ST2) signalling is necessary to prevent the development of encephalitis in mice infected with Toxoplasma gondii. Eur J Immunol 40(2):426–436
14. Lee YH, Channon JY, Matsuura T, Schwartzman JD, Shin DW, Kasper LH (1999) Functional and quantitative analysis of splenic T cell immune responses following oral toxoplasma gondii infection in mice. Exp Parasitol 91(3):212–221
15. Liew FY, Pitman NI, McInnes IB (2010) Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 10(2):103–110
16. Lin J, Zhang L, Zhao G, Su Z, Deng R, Pflugfelder SC, Li DQ (2013) A novel interleukin 33/ST2 signaling regulates inflammatory response in human corneal epithelium. PLoS One 8(4):e60963
17. Lu F, Huang S, Kasper LH (2003) Interleukin-10 and pathogenesis of murine ocular toxoplasmosis. Infect Immun 71(12):7159–7163
18. Maenz M, Schlüter D, Liesenfeld O, Schares G, Gross U, Pleyer U (2014) Ocular toxoplasmosis past, present and new aspects of an old disease. Prog Retin Eye Res 39:77–106
19. Matsuda A, Okayama Y, Terai N, Yokoi N, Ebihara N, Tanioka H, Kawasaki S, Inatomi T, Katoh N, Ueda E, Hamuro J, Murakami A, Kinoshita S (2009) The role of interleukin-33 in chronic allergic conjunctivitis. Invest Ophthalmol Vis Sci 50(10):4646–4652
20. Milovanovic M, Volarevic V, Radosavljevic G, Jovanovic I, Pejnovic N, Arsenijevic N, Lukic ML (2012) IL-33/ST2 axis in inflammation and immunopathology. Immunol Res 52(1–2):89–99
21. Niederkorn JY (2006) See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol 7(4):354–359
22. Rodríguez-Cerdeira C, Lopez-Bárcenas A, Sánchez-Blanco B, Arenas R (2014) The role of IL-33 in host response to Candida albicans. Sci World J 2014:340690
23. Rostan O, Gangneux JP, Piquet-Pellorce C, Manuel C, McKenzie AN, Guiguen C, Samson M, Robert-Gangneux F (2013) The IL-33/ST2 axis is associated with human visceral leishmaniasis and suppresses Th1 responses in the livers of BALB/c mice infected with Leishmania donovani. MBio 4(5):e00383-13
24. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type2-associated cytokines. Immunity 23(5):479–490
25. Streilein JW, Ohta K, Mo JS, Taylor AW (2002) Ocular immune privilege and the impact of intraocular inflammation. DNA Cell Biol 21(5–6):453–459
26. Suzuki Y, Yang Q, Yang S, Nguyen N, Lim S, Liesenfeld O, Kojima T, Remington JS (1996) IL-4 is protective against development of toxoplasmic encephalitis. J Immunol 157(6):2564–2569
27. Suzuki Y, Sher A, Yap G, Park D, Neyer LE, Liesenfeld O, Fort M, Kang H, Gufwoli E (2000) IL-10 is required for prevention of necrosis in the small intestine and mortality in both genetically resistant BALB/c and susceptible C57BL/6 mice following peroral infection with Toxoplasma gondii. J Immunol 164(10):5375–5382
28. Torres-Morales E, Taborda L, Cardona N, De-la-Torre A, Sepulveda-Arias JC, Patarroyo MA, Gomez-Marin JE (2014) Th1 and Th2 immune response to P30 and ROP18 peptides in human toxoplasmosis. Med Microbiol Immunol 203(5):315–322
29. Villeret B, Brault L, Couturier-Maillard A, Robinet P, Vasseur V, Secher T, Dimier-Poisson I, Jacobs M, Zheng SG, Quesniaux VF, Ryffel B (2013) Blockade of IL-1R signaling diminishes Paneth cell depletion and Toxoplasma gondii induced ileitis in mice. Am J Clin Exp Immunol 2(1):107–116
30. + T cells. Eur J Immunol 41(11):3351–3360
31. Zaiss MM, Maslowski KM, Mosconi I, Guenat N, Marsland BJ, Harris NL (2013) IL-1β suppresses innate IL-25 and IL-33 production and maintains helminth chronicity. PLoS Pathog 9(8):e1003531
32. Zhao Q, Chen G (2014) Role of IL-33 and its receptor in T cell-mediated autoimmune diseases. Biomed Res Int 2014:587376
33. Zhao WH, Hu ZQ (2012) Up-regulation of IL-33 expression in various types of murine cells by IL-3 and IL-4. Cytokine 58(2):267–273
34. Zheng Q, Ren Y, Reinach PS, She Y, Xiao B, Hua S, Qu J, Chen W (2014) Reactive oxygen species activated NLRP3 inflammasomes prime environment-induced murine dry eye. Exp Eye Res 125C:1–8